The global healthcare industry experienced a 16% decline in the number of cybersecurity-related patent applications in Q1 2023 compared with the previous quarter. The total number of cybersecurity-related grants dropped by 27% in Q1 2023, according to GlobalData’s Patent Analytics. GlobalData’s Cybersecurity in Healthcare – Thematic Research market report provides a detailed understanding on how Cybersecurity impacts the value chain in the Healthcare sector, and the leading Cybersecurity adopters and vendors in the market. Buy the report here.

Notably, the number of cybersecurity-related patent applications in the healthcare industry was 334 in Q1 2023, versus 399 in the prior quarter.

The top five companies accounted for 16% of patenting activity

Analysis of patenting activity by companies shows that Abbott Laboratories filed the most cybersecurity patents within the healthcare industry in Q1 2023. The company filed 23 cybersecurity-related patents in the quarter, compared with 2 in the previous quarter. It was followed by Johnson & Johnson with 12 cybersecurity patent filings, Siemens (8 filings), and Becton Dickinson and Co (7 filings) in Q1 2023.

Patenting activity was driven by China with a 34% share of total patent filings

The largest share of cybersecurity related patent filings in the healthcare industry in Q1 2023 was in China with 34%, followed by the US (10%) and Japan (7%). The share represented by China was 0.91% lower than the 35% share it accounted for in Q4 2022.

To further understand GlobalData's analysis on Cybersecurity in Healthcare - Thematic Research buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.